Task: Translation
Input (Czech): N-Oxid derivátu 4-fenylpyridinu vzorce I, kde R je C.sub.1-7.n. alkyl nebo halogen; R.sup.1.n. je H; R.sup.2.n. a R.sup.2´.n. je H, halogen, trifluormethyl nebo C.sub.1-7.n. alkoxy, nebo R.sup.2 .n.a R.sup.2´ .n.dohromady predstavují skupinu CH=CH-CH=CH-, která je poprípade substituována 1-2 substituenty zvolenými z C.sub.1-7.n. alkylu nebo C.sub.1-7.n. alkoxylu; R.sup.3.n. a R.sup.3´ .n.je H nebo C.sub.1-7.n. alkyl; R.sup.4.n. a R.sup.4´.n. dohromady spolu s atomem N, k nemuz jsou pripojeny, predstavují cyklickou terciární aminoskupinu zvolenou ze souboru sestávajícího z morfolin-4-ylové, piperidin-1-ylové, pyrrolidin-1-ylové, piperazin-1-ylové a 1,1-dioxothiomorfolin-4-ylové skupiny; R.sup.6.n. je H nebo C.sub.1-7.n. alkyl; X je -C(O)N(R.sup.6.n.)- nebo -N(R.sup.6.n.)C(O)-; a n je 0, 1, 2, 3 nebo 4; a jejich farmaceuticky prijatelné adicní soli s kyselinami. Tato sloucenina je prolécivem príslusného aminu, který je uzitecný pro lécení chorob majících vztah k antagonistum NK-1 receptoru. Zpusob prípravy tohoto N-oxidu a lécivo s jeho obsahem.
Output (English): The N-oxide of the 4-phenylpyridine derivative of formula I wherein R is C.sub.1-7.n. alkyl or halogen; R.sup.1.n. is H; R.sup.2.n. and R.sup.2´.n. is H, halogen, trifluoromethyl or C.sub.1-7.n. alkoxy, or R.sup.2, R.sup.2, taken together represent CH = CH-CH = CH-, which is optionally substituted with 1-2 substituents selected from C.sub.1-7.n . alkyl or C.sub.1-7.n. alkoxy; R.sup.3.n. and R.sup.3 '.n. is H or C.sub.1-7.n. alkyl; R.sup.4.n. and R.sup.4´.n. together with the N atom to which they are attached represent a cyclic tertiary amino group selected from the group consisting of morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, piperazin-1-yl and 1,1-dioxothiomorpholine. 4-yl groups; R.sup.6.n. is H or C.sub.1-7.n. alkyl; X is -C (O) N (R 6) - or -N (R 6 ') C (O) -; and n is 0, 1, 2, 3 or 4; and pharmaceutically acceptable acid addition salts thereof. This compound is a prodrug of the respective amine that is useful for treating diseases related to NK-1 receptor antagonists. A method for preparing the N-oxide and a medicament containing it.